Tenax Therapeutics Inc (TENX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.94+8.99%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Tenax plans to share study data in Q3 2026. It expects cash to last through 2027. Recent earnings beats show some progress. The company has positive M&A deals with Orion.
Tenax is still losing money with no revenue growth. Analysts expect negative EPS through 2027. Past earnings misses show risks. Cash may not last if progress stalls.
The market has no clear price or growth expectations. Estimates show ongoing losses. Our view sees some recovery but with risks.
Breaks if: Cash runs out before end of 2027
Breaks if: EPS loss worsens beyond -$1.44 in 2026 or -$1.39 in 2027
Breaks if: Data not shared by Q3 2026
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making, but it operates in a sector with favorable trends, which could provide support for future growth.
The market seems to have low fragility expectations, indicating that it does not anticipate significant negative developments. However, recent financial performance has not matched that of its industry peers, suggesting that expectations may be cautious.
Management has shown stability and is focused on advancing clinical trials and funding operations. Recent performance has been mixed, with some positive earnings results but overall momentum declining.
The long-term thesis hinges on the outcomes of ongoing clinical trials and the broader healthcare sector's performance. Key scenarios include potential guidance cuts or favorable earnings from sector leaders that could influence TENX's trajectory.
Over the next 1 to 3 years, TENX's performance will depend on its clinical trial results and market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
The recent news cuts both ways. It is challenged by fund operations through 2027 and beyond. It is supported by report topline data from phase 3 level trial in q3 2026.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.